ArticleBMC cancer2021

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.

Ramon Gonzalez Manzano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.